Skip to main content
Premium Trial:

Request an Annual Quote

Isis Appoints Lab Equipment Exec President of Functional Genomics Division

NEW YORK, June 4 – Isis Pharmaceuticals has appointed Richard Brown to lead its GeneTrove functional genomics division, the company said Monday.

Brown, formerly president of Irori, the technology and instrumentation division of Discovery Partners International, a combinatorial chemistry company, will oversee all scientific and business operations of the division, including the launch of the GeneTrove Gene Function Database later this year.

Prior to serving as president of Irori, Brown spent 13 years at Zymark, a manufacturer of automated laboratory equipment, and three years at Jarrell-Ash, a spectrometer maker now part of Thermo Jarrell-Ash.

“Rick's primary objective is to run GeneTrove as a highly competitive business and make it the premier entry in the functional genomics arena,” Isis CEO Stanley Crooke said in a statement. “By combining his commercialization experience with the quality and efficiency of GeneTrove's antisense approach to gene target validation, we believe GeneTrove is well-positioned to be the functional genomics service of choice."

Isis’ GeneTrove division focuses on using antisense technology to provide functional genomics services for pharmaceutical customers. On May 25, Isis and Hybridon signed a $40 million cross-licensing deal that consolidated control of antisense technology between the two companies. In addition, Isis is involved in drug discovery, with one HIV-related drug on the market and two in late-stage development.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.